Accellta

Company Overview

Snapshot

Founded in November 2012, Accellta operates with 11–50 employees. The company has secured funding across 3 rounds from 2 investors. In January 2024, Accellta received a grant from the Israel Innovation Authority.

Business overview

Accellta specializes in the large-scale production of embryonic and induced pluripotent stem cells, progenitors, and differentiated cells. The company's core technology utilizes 3D carrier-free suspension systems under feeder-free, adherent-free, and xeno-free conditions to optimize production efficiency, reduce costs, and maintain consistent quality. Accellta's products are applied in cell banking, drug discovery, regenerative medicine, and scientific research, serving markets within the Health Tech & Life Sciences sector, particularly in Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In January 2024, Accellta received a grant from the Israel Innovation Authority for a Proof of Concept (POC) related to dairy innovation and cultivated milk fat. This indicates the company's strategic expansion beyond traditional regenerative medicine applications into the food technology sector, leveraging its expertise in cell culturing for novel product development. This move signals a potential diversification of revenue streams and a broader market opportunity for Accellta's core technology.

Company Intelligence Q&A

What was a significant recent development for Accellta?

In January 2024, Accellta received a grant from the Israel Innovation Authority for a Proof of Concept (POC) related to dairy innovation and cultivated milk fat.

What was the nature of Accellta's collaboration with Hitachi Chemical?

In March 2018, Hitachi Chemical signed a Technical License Agreement with Accellta to utilize Accellta's stem cell culture media and methods. This aimed to strengthen Hitachi Chemical's capabilities in contracted cell manufacturing for clinical and regenerative applications.

What was the outcome of the collaboration between Nano Dimension and Accellta?

In May 2016, Nano Dimension and Accellta successfully bioprinted stem cell-derived tissues, confirming the viability of printing stem cells using an adapted 3D printer. The companies considered forming a new entity for future solutions in 3D bioprinting.

What was the collaboration between Cellect Biomed and Accellta about?

In April 2016, Cellect Biomed and Accellta signed a collaboration agreement. Accellta gained a nonexclusive right to evaluate the impact of Cellect's apoptotic induction-based technology on its stem cell culturing methods, aiming for safer and faster growth of pluripotent cells.

What was the partnership with Thermo Fisher Scientific?

In June 2015, Accellta granted worldwide non-exclusive rights to Thermo Fisher Scientific for the manufacture and distribution of its proprietary feeder-free stem cell culture medium and ancillary products. This partnership aimed to enable homogeneous growth of stem cell production.